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Résumé en français 
Jusqu'alors, il n'avait jamais été formellement démontré qu'une forte dose d'un antagoniste 
de !'angiotensine II à longue durée d'action pouvait être aussi efficace sur le blocage du 
système rénine-angiotensine que l'association d'un inhibiteur de l'enzyme de conversion avec 
le même antagoniste de !'angiotensine II à des doses plus faibles. Dans cette étude randomisée 
en double aveugle, nous avons étudié le blocage du système rénine-angiotensine obtenu avec 
trois doses d'olmesaiian medoxomil (20, 40 et 80 mg) chez 30 volontaires sains que nous 
avons comparé au blocage obtenu par du lisinopril (20 mg), seul ou associé à de l'olmesartan 
medoxomil (20 et 40 mg). L'étude s'est déroulée en deux phases selon un design par 
crossover. A deux reprises, chaque volontaire à reçu durant une semaine l'un des six 
traitements possibles. Un intervalle d'une semaine a été respecté entre les deux phases 
(période de washout). L'objectif principal était d'étudier, 24 heures après la dernière dose, le 
blocage de l'élévation de la pression systolique en réponse à l'administration d'angiotensine I. 
Ce blocage était de 58% ± 19% (moyenne± déviation standard) avec 20 mg de lisinopril, de 
58% ± 11 % avec 20 mg d'olmesartan medoxomil, de 62% ±16% avec 40 mg d'olmesartan 
medoxomil, et de 76% ± 12% avec la plus forte dose d'olmesartan medoxomil (80 mg) (P= 
.016 versus 20 mg de lisinopril et P=.0015 versus 20 mg d'olmesartan medoxomil). Le 
blocage était de 80% ±22% avec 20 mg de lisinopril associé à 20 mg d'olmesartan medoxomil 
et de 83% ± 9% avec 20 mg de lisinopril associé à 40 mg d'olmesartan medoxomil (P= .3 
versus 80 mg d'olmesartan medoxomil). Ces résultats montrent, que chez les volontaires 
sains, une dose suffisamment élevée d'olmesartan medoxomil peut induire un blocage à 24 
heures quasi complet de l'élévation de la pression artérielle en réponse à l'administration 
d'angiotensine I. De même, en terme de blocage de l'effet vasculaire de !'angiotensine I, une 
dose suffisamment élevée d'un antagoniste de l'angiotensine II de longue durée d'action est 
tout aussi efficace que ce même antagoniste à des doses plus faibles associé avec à un 
inhibiteur de l'enzyme de conversion. 
Sustained 24-hour block:ade of the 
renin-angiotensin system: A high dose of a 
long-acting bloclcer is as effective as 
a lower dose combined with an 
angiotensin-converting enzyme inhibitor 
Whether a higher dose of a long-acting angiotensin II receptor blocker (ARB) eau provide as much blockade 
of the renin-angiotensin system over a 24-hour period as the combination of an angiotensin-converting 
enzyme inhibitor and a lower dose of ARB has not been form.ally demonstrated so far. In this randomized 
double-blind study we investigated renin-angiotensin system blockade obtained with 3 doses of olmesartan 
medoxomil (20, 40, and 80 mg every day) in 30 normal subjects and compared it with that obtained with 
lisinopril alone (20 mg every day) or combined wi!h olmesartan medoxomil (20 or 40 mg). Bach subject 
received 2 dose regimens for 1 week according to a crossover design with a 1-week washout period between 
doses. The primary endpoint was the degree ofblockade of the systolic blood pressure response to angiotensin 
I 24 hours after the last dose after 1 week of administration. At trough, the systolic blood pressure response 
to exogenous angiotensin I was 58% ± 19% with 20 mg lisinopril (mean ± SD), 58% ± 11% with 20 mg 
olmesartan medoxomil, 62% ± 16% with 40 mg olmesartan medoxomil, and 76% ± 12% with the highest dose 
of olmesartan medoxomil (80 mg) (P = .016 versus 20 mg lisinopril and P = .0015 versus 20 mg olmesartan 
medoxomil). With the combinations, blockade was 80% ± 22% with 20 mg lisinopril plus 20 mg olmesa11:an 
medoxomil and 83% ± 9% with 20 mg lisinopril plus 40 mg olmesartan medoxomil (P = .3 ve1·sus 80 mg 
olmesartan medoxomil alone). These data demonstrate that a higher dose of the long-acting ARB olmesartan 
medoxomil eau produce an almost complete 24-hour blockade of the blood pressure response to exogenous 
angiotensin in normal subjects. Hence, a higher dose of a long-acting ARB is as effective as a lower dose of the 
same compound combined with an angiotensin-converting enzyme inhibitor in terms of blockade of the 
vascular effects of angiotensin. (Clin Pharmacol Ther 2005;78:501-7.) 
Christopher Hasler, MD, Jürg Nussberger, MD, Marc Maillard, PhD, 
Andrei Forclaz, MD, Hans R. Brunner, MD, and Michel Burnier, MD 
Lausanne, S1vitzerland 
Blockade of the renin-angiotensin system (RAS) with 
angiotensin-converting enzyme inhibitors (ACEls) or an-
giotensin II receptor blockers (ARBs) represents an effec-
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tive therapeutic approach to treat hypertension and con-
gestive heart failure and to prevent the progression of 
diabetic and nondiabetic renal disease. 1 This has estab-
lished angiotensin II as a key factor contributing to blood 
pressure increase and multiple organ damage. As a con-
sequence, blockade of the synthesis or action of angioten-
sin II around the dock becomes a clear therapeutic goal, 
particularly because complete blockade of the RAS does 
not seem to elicit untoward effects. In recent years several 
studies have suggested that a greater and more sustained 
blockade of the RAS could be obtained with the combi-
nation of an ACEI and an ARB and that the ACEI-ARB 
combination may provide additional clinical benefits 
when compared with either drug alone.2-6 This hypothesis 
has been supported by the recent results of trials con-
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ducted in patients with diabetic and nondiabetic nephrop-
athies and in patients with heart failure.7-9 
Early studies have demonstrated that it is very diffi-
cult to obtain a complete 24-hour blockade of the RAS 
with an ACEI because angiotensin II can be generated 
by other enzymatic pathways and also because with an 
ACEI, as a result of the reactive increase in plasma 
renin activity, angiotensin II is produced as soon as 
some angiotensin-converting enzyme (ACE) activity 
reappears. 10- 13 We have also demonstrated previously 
that several AREs do not induce a complete 24-hour 
blockade of the receptor at their recommended doses in 
healthy subjects. 14' 15 Hence the combination with an 
ACEI is indeed expected to increase and prolong the 
blockade of the RAS because both compounds provide 
only a partial blockade per se. However, we have also 
shown recently that an increase in the dose of the ARB 
or a twice-daily administration of some ARBs with a 
shorter duration of action could produce as much block-
ade of the RAS as an ACEI-ARE combination. 16 Thus 
a potent, long-acting ARE could conceivably be as 
effective as an ACEI-ARE combination to induce a 
sustained 24-hour blockade of the RAS, provided that 
the dose of the drng is chosen and characterized appro-
priately. Such a compound would of course have the 
advantages of simplifying the treatment (only 1 drug to 
administer) and avoiding the potential sicle effects of 
A CEis. 
In this study, we investigated the blockade of the 
RAS obtained with 3 doses of olmesartan medoxomil, 
an ARE with a relatively long half-life, in normoten-
sive subjects and compared it with that obtained with 
lisinopril alone or combined with a lower dose of 
olmesartan medoxomil. 
METHODS 
Subjects. Thirty normotensive male subjects were 
enrolled in this study (26 white subjects and 4 nonwhite 
subjects). The mean age was 23.9 years (range, 20-35 
years), and the mean body mass index was 21.6 kg/m2 
(range, 19.0-26.0 kg/m2). 
Ali subjects were considered to be healthy on the 
basis of medical history, physical examination, routine 
blood and urine analyses, and an electrocardiogram. 
None had a family history of hypertension. The study 
protocol was approved by our institutional review com-
mittee. Written consent was obtained from each volun-
teer after the nature, purpose, and potential risks of the 
study were explained. 
Study design. In this double-blind crossover study the 
volunteers were distributed into 6 groups, and within each 
group, each subject was randomized to receive 2 treat-
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ments for 1 week, separated by a 4-week washout 
period. During the last 3 days of each treatment, sub-
jects received a 100-mmol sodium diet at the hospital. 
In each treatment phase, one of the following regimens 
w_as randomly assigned: 20 mg lisinopril every day, 20 
mg olmesartan medoxomil every day, 40 mg olmesar-
tan medoxomil every day, 80 mg, olmesartan medox-
omil every day, 20 mg olmesartan medoxomil plus 20 
mg lisinopril every day, and 40 mg olmesartan medox-
omil plus 20 mg lisinopril every day. To maintain 
double-blindness, placebo tablets were given to the 
subjects randomized to a single therapy. Blockade of 
the RAS was assessed at 0 and 4 hours on day 1 without 
drug intake to determine the baseline value and again at 
0 and 4 hours on the last day of treatment (day 8). On 
each investigational day, volunteers were asked to 
corne to our research facility after an overnight fast. 
They were comfortably situated in a supine position, 
and a venous catheter was placed in each forearm, one 
for blood sampling and the other for the intravenous 
injection of angiotensin I (Clinalfa, Uiufelfingen, 
Switzerland). At each time point (0 and 4 hours), the 
short-term changes in blood pressure induced by the 
administration of exogenous angiotensin I were mea-
sured by photoplethysmography at the finger as de-
scribed previously .17 The doses of angiotensin I were 
defined for each subject on day 1 to increase systolic 
blood pressure by at least 25 mm Hg. Thus the doses 
ranged between 20 and 60 ng/kg depending on the 
subjects. Thereafter the same dose of angiotensin 1 was 
readministered on day 1 at 4 hours and on day 8 at 0 
and 4 hours. In addition, blood was taken to measure 
plasma renin activity and plasma angiotensin II lev.els 
before the administration of exogenous angiotensin 1. 
During the entire study, the volunteers were asked to 
corne back every morning to receive the drugs under 
medical supervision. 
Blood pressure measurement and hormonal mea-
surements. Elood pressure response to exogenous angio-
tensin I was monitored noninvasively by photoplethys-
mography at the finger (Finapress; Ohmeda, Englewood, 
Conn). The photoplethysmograph was calibrated every 
day on the basis of blood pressure measured at the aim. 
The system has been validated previously. 18 Blood pres-
sure was also measured with a standard sphygmomanom-
eter at trough before administration of any dose of exog-
enous angiotensin on days 1 and 8 to monitor the 
sustained effects of the drng regimens on blood pressure. 
Blood was drawn at the same time of day in each group to 
standardize the measurements. Plasma renin activity was 
measured by use of a radioimmunologic microassay based 
on angiotensin I trapping by antibody. Angiotensin II 
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Table 1. Changes in trough supine blood pressure observed after 1 week of drug administration 
.. Base li ne Change in Change in 
blood systolic diastolic 
Dose pressure blood pressure p blood pressure p 
(mg) (mm Hg) (mm Hg)* value (mm Hg)* value 
Lisinopril 20 117/68 -2.9 ± 5.8 .15 -1.7 ± 5.8 .38 
Olmesartan medoxomil 20 114/66 -5.6 ± 6.9 .031 -3.0 ± 4.2 .051 
Olmesartan medoxomil 40 113/65 -6.2 ± 5.6 .006 -5.6 ± 5.1 .007 
Olmesartan medoxomil 80 117/67 -5.9 ± 5.8 .010 -2.8 ± 4.9 .103 
Olmesartan medoxomil + 20 mg 20 115/67 -10.3 ± 8.3 .003 -5.6 ± 8.2 .060 
lisinopril 
Olmesartan medoxomil + 20 mg 40 116/66 -6.7 ± 7.2 .016 -5.1 ± 5.1 .011 
lisinopril 
Ali values are presented as mean :t SD. Baseline values were measured on day l at time O. 
*Blood pressure was measured with a conventional sphygmomanometer. 
concentration was dete1mined by use of a monoclonal 
antibody binding assay. 19 
Statistical analysis. Ali results are presented as 
mean ± SD unless otherwise specified. As mentioned 
previously, the primary endpoint was the systolic blood 
pressure response to exogenous angiotensin I at 24 
hours. Ali analyses were performed in a double-blind 
manner. Our study was powered to conclude on a 
difference in blockade greater than 15%. One~way 
ANOV A was performed, followed by either paired or 
unpaired t tests by use of GraphPad Prism version 3.00 
for Windows (GraphPad Software, San Diego, Calif). 
P < .05 was considered to be statistically significant. 
RESULTS 
Ali doses of olmesartan medoxomil and lisinopril 
were well tolerated. Compliance to drug treatment was 
100%. In the 6 groups of subjects, the median 24-hour 
urinary sodium excretion on day 1 of the first treatment 
phase ranged between 106 and 137 mmol/24 hours, 
with no significant difference between the groups. On 
the first day of the second treatment phase, 24-hour 
urinary sodium excretion was slightly higher, with a 
median for each group ranging between 109 and 
160 mmol/24 hours, suggesting that the compliance to 
the diet decreased from the first to the second phase. 
Again, no statistical difference between the groups was 
observed. One subject had to be withdrawn and re-
placed because mild alterations of hepatic test results 
developed with the administration of olmesartart med-
oxomil in this subject. These alterations normalized 
after interruption of olmesartan medoxomil. Three 
months later, liver function was normal and no diagno-
sis of viral hepatitis could be retained. This suggests 
that the alterations were probably due to the adminis-
tration of olmesartan medoxomil. 
As shown in Table 1, after 1 week of administration, 
a significant decrease in systolic blood pressure was 
observed with all doses except for 20 mg lisinopril 
every day. The changes in diastolic blood pressure were 
Jess consistent, with significant decreases observed 
only with 40 mg olmesartan medoxomil and the com-
bination of 40 mg olmesartan medoxomil and 20 mg 
lisinopril. The changes in systolic and diastolic blood 
pressure induced by the 2 olmesartan medoxomil-
lisinopril combinations were not different from those 
obtained with the 3 doses of olmesartan medoxomil 
alone. 
After 1 week of administration, al! treatment _sched-
ules induced a marked blockade (>80%) of the blood 
pressure response to exogenous angiotensin I 4 hours 
after drug intake, and there was no significant differ-
ence between the doses (Fig 1). In contrast, the block-
ade of the RAS obtained at trough (time 0) on day 8 
differed depending on the dose administered, as shown 
in Fig 1. Thus the systolic blood pressure response to 
exogenous angiotensin I was blocked by 58% ± 19% 
with 20 mg lisinopril, 58% ± 11 % with 20 mg olme-
sartan medoxomil, 62% ± 16% with 40 mg olmesartan 
medoxomil, and 76% ± 12% with the highest dose of 
olmesartan medoxomil (80 mg). At the same time 
point, the response to angiotensin 1 was blunted by 80% 
± 22% with 20 mg olmesartan medoxomil plus 20 mg 
lisiriopril and by 83% ± 9% with 40 mg olmesartan 
medoxomil plus 20 mg lisinopril. The combinations 
provided significantly more blockade than either drug 
alone but were not greater than that with the highest 
dose of olmesartan medoxomil (80 mg every day). 
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Fig 1. Summary of blockade of systolic blood pressure 
(SBP) response to exogenous angiotensin I (Ang I), after 1 
week of treatment, at trough (ie, before dosing on day 8) 
(upper panel) and 4 hours after dosing on day 8 (lower panel) 
in different study groups. Data are presented as mean :': SD. 
At trough (upper panel), 80 mg olmesartan medoxomil (Olm) 
(P = .016), 20 mg olmesartan medoxomil plus 20 mg lisin-
opril (Lis) (P = .0028), and 40 mg olmesartan medoxomil 
plus 20 mg lisinopril (P = .0123) were significantly different 
from 20 mg lisinopril. In addition, 80 mg olmesartan medox-
omil (P = .0015), 20 mg olmesartan medoxomil plus 20 mg 
lisinopril (P = .041), and 40 mg olmesartan medoxomil plus 20 
mg Iisinopril (P =' .001) were also significantly different from 
20 mg olmesartan medoxomil. Finally, 40 mg olmesartan" 
medoxomil plus 20 mg Iisinopril (P = .008) and 80 mg 
olmesartan medoxomil (P = .05) were significantly different 
from 40 mg olmesartan medoxomil. The other comparisons 
between groups were not significant. At 4 hours (lower 
panel), ail groups were comparable statistically. 
Table II shows the changes in plasma renin activity 
and plasma angiotensin II levels induced by the various 
dose schedules in our subjects. As expected, increasing 
the dose of olmesartan medoxomil induced a dose-
dependent increase in plasma renin activity at trough 
and comparable changes at 4 hours. As far as renin is 
concerned, the olmesartan medoxomil-lisinopril com-
binations were superior to 20 mg lisinopril and 20 mg 
olmesartan medoxomil but were not different from the 
40- and 80-mg doses of olmesartan medoxomil. As 
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expected, plasma angiotensin II 1evels were reduced 
under ACE inhibition and were significantly lower with 
the olmesartan medoxomil-lisinopril combinations 
than "'.ith olmesartan medoxomil alone on day 8. The 
statistical differences between the groups are shown in 
Table III. 
DISCUSSION 
Taken together, the results of this study demonstrate 
that the long-acting ARB olmesartan medoxomil can 
produce an almost complete 24-hour blockade of the 
RAS at the dose of 80 mg once daily for l week in 
normotensive subjects. Combining a lower dose of the 
same ARB with an ACEI does not provide a greater 
blockade of the system at least in terms of inhibition of 
the vasoconstrictor effects of angiotensin. Hence the 
use of a higher dose of a well-tolerated angiotensin II 
antagonist may be a good alternative to the ACEI-
angiotensin H antagonist combination. 
Given that there exists extensive evidence that an-
giotensin II may exert detrimental vascular effects be-
yond raising blood pressure,20•21 it would seem logical 
to pursue as a treatment target complete blockade of the 
RAS around the clock. At their recommended doses, 
few of the angiotensin II receptor antagonists, if any, 
have been found to induce a complete blockade of the 
RAS around the clock. Yet in an earlier study we have 
provided evidence that this can be achieved with losar-
tan alone administered at a dose of 100 mg twice a 
day. 16 The present results demonstrate that the same 
goal can be achieved with olmesartan medoxomil ad-
ministered only once per 24 hours. Whether marked 
blockade of the RAS at trough versus incomplete 
blockade indeed translates into better outcome in hy-
pertensive patients still needs to be further investigated 
but a priori seems reasonable to expect. Thus the out-
come of the VALUE (valsartan antihypertensive long-
term use evaluation) trial would perhaps have been 
different if valsartan had been given at higher doses and 
possibly twice a day as in the ValHeft (valsartan heart 
failure trial) study.22•23 
Blockade of the RAS for the duration of 24 hours can 
be achieved very well by the combination of relatively 
low doses of an ARB with an ACEI. 2-4 The potential 
limitation with the combination lies in the side effects 
of the ACEis. In contrast to ACEis, ARBs have not 
exhibited any typical class side effects thus far. 24 Thus 
even high doses of ARBs, which provide sustained 
blockade and are hoped to enhance organ protection, 
will probably do this without causing any untoward 
effects. This unique combination of substantial and 
sustained efficacy with a favorable tolerability profile 
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Table II. Plasma renin activity and plasma angiotensin II levels in different study groups 
Plasma renin activity (ng mC1 • h-1) Plasma angiotensin Il levels (fmollmL) 
Day 1 (baseline) Day 8 Day 1 (baseline) Day 8 
Oh 4h Oh 4h 
Treatment Oh 4h (trough) (peak) Oh 4h (~rough) (peak) 
Lis 20 1.5 ::':: 1.0 1.1 ::':: 1.2 9.3 ::':: 6.6 21.7 ::':: 15.4 3.8 ::':: 0.9 2.6 ::':: 0.8 3.5 ± 1.7 1.2 ::':: l.O 
Olm 20 1.5 ::':: 0.5 1.5 ::':: 0.7 4.5 ::':: 6.8 13.7 ± 16.9 5.3 ::':: 1.7 4.8 ::':: 2.8 26.8 ::':: 13.2 89 ::':: 72 
Olm 40 1.5 ± 1.0 1.9 ::':: 1.2 11.0 ::':: 6.6 26.8 ± 15.4 3.8 ::':: 1.3 3.3 ::':: 1.8 54.3 ± 31.2 128 ::':: 116 
Olm 80 1.4 ± 0.5 1.4 ::':: 0.7 14.6 ± 6.8 27.0 ::':: 16.9 3.3 ::':: 2.5 3.7 ± 1.9 69.9 ::':: 55.4 144 ::':: 109 
Olm 20 + Lis 20 1.3 ::':: 0.8 1.4 ::':: 0.8 19.1 ± 18.6 33.6 ± 32.9 2.7 ::':: 1.2 3.6 ::':: 1.7 8.0 ::':: 5.8 3.2 ::':: 1.6 
Olm 20 +Lis 20 1.3 ::':: 0.4 1.6 ::':: 0.7 22.4 ::':: 15.7 30.6 ::':: 26.0 3.8 ::':: 1.4 4.2 ::':: 2.3 8.4 ::':: 3.2 2.5 ::':: 1.2 
Values are given as mean ± SD. 
Lis, Lisinopril; Olm, ofmesartan medoxomil. 
Table III. Statistical differences in plasma renin activity and plasma angiotensin II levels in different groups 
Treatment Lis 20 Olm 20 Olm 40 Olm 80 Olm 20 + Lis 20 Olm 40 + Lis 20 
Plasma renin activity (P value between 





Olm 20 + Lis 20 
Olm 40 + Lis 20 
Plasma angiotensin II levels (P value 
between different study groups at 





Olm 20 + Lis 20 
Olm 40 + Lis 20 
.07/.18 
.001/.003 
renders this treatment very attractive for potential long-
term organ protection. As shown in our study, the main 
difference between a high dose of an angiotensin II 
receptor antagonist and a combination of an ACEI and 
an ARB is the circulating level of angiotensin II. In the 
former situation, angiotensin II levels are very much 
increased, whereas in the latter situation, angiotensin II 
levels are moderately increased. Whether these differ-
ences in circulating angiotensin II have a clinical im-
pact is difficult to appreciate. Indeed, high angiotensin 
II levels may stimulate the unblocked angiotensin AT2 
receptors. However, the clinical impact of long-term 
stimulation of AT 2 receptors is not known. Similarly, 
one could argue that other pharmacologie properties of 
ACE inhibition such as bradykinin generation may 
.24/.60 .13/.98 .07/.34 .048/.31 
.042/.07 .008/.23 .04/.10 .005/.09 
.30/.53 . l l/.46 .09/.65 
.39/.08 .21/.38 
.74/.88 
.001/.007 .005/.002 .054/.017 .001/.016 
.041/.45 .052/.22 .004/.004 .001/.004 
.43/.53 .001/.007 .001/.007 
.006/.002 .008/.002 
.8 l/.32 
have some additive value in favor of the combination, 
but this has not been formerly demonstrated either. Of 
note, significant decreases in systolic blood pressure 
were observed in our otherwise normotensive subjects 
with the administration of olmesartan medoxomil alone 
or in association with the ACE!, whereas lisinopril 
alone at the dose of 20 mg every day had no effect on 
blood pressure. The changes in blood pressure can be 
explained by the fact that subjects were moderately 
salt-depleted because they received a diet of 100-mmol 
sodium per day for the 3 days preceding each investi-
gation with exogenous angiotensin II. 
As discussed in previous reports, a possible limi-
tation of our observation is that it has been obtained 
in normotensive healthy subjects receiving normal 
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salt intake (ie, with a reactive RAS). 16 Hence our 
observation may not apply to all types of hyperten-
sive patients. Thus patients with low renin activity 
(elderly or hypertensive patients rece1vmg a 
[3-blocker) may not necessarily benefit from a higher 
dose of ARB, but whether these patients would ben-
efit from a combination of ACEI and ARB is also 
questionable. In low-renin conditions, combined 
blockade of the RAS with 150 mg irbesartan and 20 
mg fosinopril appeared to be superior to receptor 
blockade alone with 300 mg irbesartan, but whether 
a higher dose of irbesartan would be as effective as 
the combination has not been evaluated. 25 Moreover, 
it is interesting to note that, besides heart failure, the 
clinical interest of combining an ACEI with an ARB 
has been demonstrated mainly in patients with non-
diabetic or diabetic nephropathy, the latter often be-
ing considered to have a low intrinsic activity of the 
RAS. 6-9 •26 In the same groups of patients, high doses 
of ARBs or ACEis have been reported to be more 
effective in reducing proteinuria or providing renal 
protection than lower doses or as effective as the 
ACEI-ARB combination.21-30 
In conclusion, several large clinical trials investi-
gating the ability of ARBs to protect hypertensive 
patients against target organ damage have now re-
peatedly shown that the highest doses were the most 
effective31 -34 and that there may be a potential for 
more aggressive treatment. These studies have also 
suggested that there may be benefits of blocking the 
effects of angiotensin II beyond blood pressure con-
trol.34 Rather complete blockade of the RAS around the 
clock can be achieved by combining an ACEI and an 
ARB or with a higher dose of a long-acting ARB, as 
demonstrated in this study with olmesartan medoxomil. 
However, monotherapy with an ARB alone as opposed 
to the combinatîon has the advantages of an absence of 
side effects and probably better compliance. On the 
basis of recent evidence from several trials, it is likely 
that more complete blockade of the RAS than hitherto 
used may become the standard for improved vascular, 
cardiac, and renal protection. Clinical studies with var-
ious ARBs are now ongoing to demonstrate that higher 
doses can indeed fulfill this expectancy. 
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